Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration

Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

doi:10.1053/j.gastro.2018.10.057

Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration

Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

Research output: Contribution to journal › Editorial

24 Scopus citations

Original language	English
Pages (from-to)	838-842
Number of pages	5
Journal	Gastroenterology
Volume	156
Issue number	4
DOIs	https://doi.org/10.1053/j.gastro.2018.10.057
State	Published - Mar 2019

Access to Document

10.1053/j.gastro.2018.10.057

Cite this

@article{483b702249164209b45deefd446f35d8,

title = "Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration",

author = "{Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)} and Gupta, {Sandeep K.} and Falk, {Gary W.} and Aceves, {Seema S.} and Mirna Chehade and Collins, {Margaret H.} and Dellon, {Evan S.} and Nirmala Gonsalves and Ikuo Hirano and Mukkuda, {Vincent A.} and Peterson, {Kathryn A.} and Jonathan Spergel and Yang, {Guang Yu} and Furuta, {Glenn T.} and Rothenberg, {Marc E.}",

note = "Funding Information: Conflicts of interest The authors have made the following disclosures: Dr Aceves reports grants from the National Institutes of Health (NIH), and oral viscous budesonide, a UCSD patented licensed to Shire Pharma, and is a consultant for Regeneron. Dr Chehade received research funding from the NIH, PCORI and Nutricia, consulting fees from Shire and Allakos, and clinical trial funding from Regeneron and Shire. Dr Collins reports grants from the NIH, during the conduct of the study; grants from Shire and grants from Regeneron, outside the submitted work. She is also Chair of the Medical Advisory Panel of the American Partnership for Eosinophilic Disorders (APFED) and an Executive Committee member of The International Group of Eosinophil Researchers (TIGERS). Dr Dellon reports grants and personal fees from Adare, Banner, Celgene/Receptos, GSK, Regeneron, and Shire; personal fees from Alivio, Allakos, AstraZeneca, Enumeral, and Robarts Clinical Trials; grants from Meritage, Miraca, Nutricia, and Holoclara. Dr Falk reports grants and personal fees from Shire, ADARE, and Regeneron; personal fees from Banner Bioscience; and grants from Allakos and Celgene, outside the submitted work. Dr Furuta reports other from EnteroTrack, Shire, and UpToDate, outside the submitted work. Dr Gonsalves has royalties from UpToDate. Dr Gupta reports personal fees from Adare, Allakos, Abbott, Receptos, and QOL; and grants from Shire, outside the submitted work. Dr Hirano reports grants and consultant fees from Adare, Shire, Regeneron, and Receptos. Dr Mukkada reports grants from the NIH; grants and personal fees from Shire Pharmaceutical, outside the submitted work. Dr Peterson has nothing to disclose. Dr Rothenberg reports grants from the NIH, US-Israel Binational Grant, and PCORI; ch; equity in Immune Pharmaceuiticals, PulmOne, and Spoon Guru; and personal fees from Glaxo Smith Kline, Merck, Allakos, AstraZeneca, Genetech, Celgene, and Regeneron; in addition, Dr Rothenberg receives royalties from UpToDate and reslizumab (Teva Pharmaceuticals). Dr Spergel reports grants and personal fees from DBV Technologies, grants from End Allergy Together, Food Allergy Research Education and Aimmune Therapeutics; personal fees from UpToDate, Regeneron, and personal fees from Shire, outside the submitted work. Dr. Yang has nothing to disclose. All other authors have nothing to disclose. Funding Information: CEGIR, a multicenter clinical research program focused on EGIDs, was first formed as part of the Rare Diseases Clinical Research Network (RDCRN) (U54 AI117804) from the NIH through the Office of Rare Diseases Research, the National Center for Advancing Translational Science, and funded by collaborative efforts of the National Center for Advancing Translational Science, the National Institute of Allergy and Infectious Diseases, and the National Institute of Diabetes and Digestive and Kidney Diseases. 6,7 To address the various facets of EGIDs, multiple components of CEGIR were created, each featuring multicenter collaborations, the accomplishments of which are highlighted herein. ",

year = "2019",

month = mar,

doi = "10.1053/j.gastro.2018.10.057",

language = "English",

volume = "156",

pages = "838--842",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Consortium of Eosinophilic Gastrointestinal Disease Researchers

T2 - Advancing the Field of Eosinophilic GI Disorders Through Collaboration

AU - Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

AU - Gupta, Sandeep K.

AU - Falk, Gary W.

AU - Aceves, Seema S.

AU - Chehade, Mirna

AU - Collins, Margaret H.

AU - Dellon, Evan S.

AU - Gonsalves, Nirmala

AU - Hirano, Ikuo

AU - Mukkuda, Vincent A.

AU - Peterson, Kathryn A.

AU - Spergel, Jonathan

AU - Yang, Guang Yu

AU - Furuta, Glenn T.

AU - Rothenberg, Marc E.

N1 - Funding Information: Conflicts of interest The authors have made the following disclosures: Dr Aceves reports grants from the National Institutes of Health (NIH), and oral viscous budesonide, a UCSD patented licensed to Shire Pharma, and is a consultant for Regeneron. Dr Chehade received research funding from the NIH, PCORI and Nutricia, consulting fees from Shire and Allakos, and clinical trial funding from Regeneron and Shire. Dr Collins reports grants from the NIH, during the conduct of the study; grants from Shire and grants from Regeneron, outside the submitted work. She is also Chair of the Medical Advisory Panel of the American Partnership for Eosinophilic Disorders (APFED) and an Executive Committee member of The International Group of Eosinophil Researchers (TIGERS). Dr Dellon reports grants and personal fees from Adare, Banner, Celgene/Receptos, GSK, Regeneron, and Shire; personal fees from Alivio, Allakos, AstraZeneca, Enumeral, and Robarts Clinical Trials; grants from Meritage, Miraca, Nutricia, and Holoclara. Dr Falk reports grants and personal fees from Shire, ADARE, and Regeneron; personal fees from Banner Bioscience; and grants from Allakos and Celgene, outside the submitted work. Dr Furuta reports other from EnteroTrack, Shire, and UpToDate, outside the submitted work. Dr Gonsalves has royalties from UpToDate. Dr Gupta reports personal fees from Adare, Allakos, Abbott, Receptos, and QOL; and grants from Shire, outside the submitted work. Dr Hirano reports grants and consultant fees from Adare, Shire, Regeneron, and Receptos. Dr Mukkada reports grants from the NIH; grants and personal fees from Shire Pharmaceutical, outside the submitted work. Dr Peterson has nothing to disclose. Dr Rothenberg reports grants from the NIH, US-Israel Binational Grant, and PCORI; ch; equity in Immune Pharmaceuiticals, PulmOne, and Spoon Guru; and personal fees from Glaxo Smith Kline, Merck, Allakos, AstraZeneca, Genetech, Celgene, and Regeneron; in addition, Dr Rothenberg receives royalties from UpToDate and reslizumab (Teva Pharmaceuticals). Dr Spergel reports grants and personal fees from DBV Technologies, grants from End Allergy Together, Food Allergy Research Education and Aimmune Therapeutics; personal fees from UpToDate, Regeneron, and personal fees from Shire, outside the submitted work. Dr. Yang has nothing to disclose. All other authors have nothing to disclose. Funding Information: CEGIR, a multicenter clinical research program focused on EGIDs, was first formed as part of the Rare Diseases Clinical Research Network (RDCRN) (U54 AI117804) from the NIH through the Office of Rare Diseases Research, the National Center for Advancing Translational Science, and funded by collaborative efforts of the National Center for Advancing Translational Science, the National Institute of Allergy and Infectious Diseases, and the National Institute of Diabetes and Digestive and Kidney Diseases. 6,7 To address the various facets of EGIDs, multiple components of CEGIR were created, each featuring multicenter collaborations, the accomplishments of which are highlighted herein.

PY - 2019/3

Y1 - 2019/3

UR - http://www.scopus.com/inward/record.url?scp=85062431181&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2018.10.057

DO - 10.1053/j.gastro.2018.10.057

M3 - Editorial

C2 - 30452923

AN - SCOPUS:85062431181

SN - 0016-5085

VL - 156

SP - 838

EP - 842

JO - Gastroenterology

JF - Gastroenterology

IS - 4

ER -